- Event and webcast scheduled on Tuesday, April 29 at 6:00 p.m. Eastern Time
CARLSBAD, Calif., April 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Tuesday, April 29, 2014 at 6:00 p.m. Eastern Time to discuss the ISIS-SMNRx data presented at the 2014 American Academy of Neurology Annual Meeting.
Interested parties may register to attend the event in Philadelphia, PA, or access the webcast on t...
CARLSBAD, Calif., April 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 8 , 2014 at 12:50 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com. A replay will be available on the Isis website within ...
- Reductions of up to 64 percent in triglycerides achieved
- Reductions in atherogenic particles and increases in HDL particles observed
- Data presented today at the American College of Cardiology
CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIR...
Data to be presented in April at the European Association for the Study of the Liver Meeting
Isis' antisense drug targeting HBV, ISIS-HBVRx, in an ongoing Phase 1 study planned to complete this year
CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of ...
If you are interested in Isis Pharmaceuticals’ investment details, please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Online Investor Kit
Quickly download files right from our Investor Relations Web site.